Dizal Pharmaceuticals’ sunvozertinib outperformed chemotherapy in a Phase 3 first-line trial in advanced NSCLC with EGFR exon 20 insertion mutations, according to results published in NEJM. In the international WU-KONG28 trial (NCT05668988), sunvozertinib improved median progression-free survival to 10.3 months versus 7.5 months with carboplatin–pemetrexed. The trial reported a higher objective response rate with sunvozertinib (58.9% vs 31.1%) and durable disease control signals at 12 months, while overall survival data were immature at analysis. Adverse events of Grade 3 or higher were reported in 75.5% of patients on sunvozertinib compared with 56.7% on chemotherapy, with no deaths attributed to treatment-related adverse events. The result expands options for EGFR exon 20–mutant patients moving earlier in the treatment sequence and could influence sequencing against existing EGFR-directed standards.